Sayer M, Webb D, Dhaun N
Nat Rev Cardiol. 2025; .
PMID: 39920248
DOI: 10.1038/s41569-025-01131-4.
Upadhyay A, Haider L
Clin Diabetes. 2025; 43(1):43-52.
PMID: 39829701
PMC: 11739366.
DOI: 10.2337/cd24-0036.
Koubsky K
Physiol Res. 2024; 73(S2):S597-S613.
PMID: 39589305
PMC: 11627266.
Sethi R, Vishwakarma P, Pradhan A
Card Fail Rev. 2024; 10:e15.
PMID: 39588014
PMC: 11588114.
DOI: 10.15420/cfr.2024.10.
Mazzieri A, Timio F, Patera F, Trepiccione F, Bonomini M, Reboldi G
Kidney Blood Press Res. 2024; 49(1):1041-1056.
PMID: 39557029
PMC: 11844674.
DOI: 10.1159/000542621.
G protein-coupled estrogen receptor: a promising therapeutic target for aldosterone-induced hypertension.
Li X, Kuang W, Qiu Z, Zhou Z
Front Endocrinol (Lausanne). 2023; 14:1226458.
PMID: 37664844
PMC: 10471144.
DOI: 10.3389/fendo.2023.1226458.
Aldosterone breakthrough from a pharmacological perspective.
Alfie J
Hypertens Res. 2023; 46(5):1350.
PMID: 36810620
DOI: 10.1038/s41440-023-01204-2.
Mineralocorticoid receptor antagonism in diabetes reduces albuminuria by preserving the glomerular endothelial glycocalyx.
Crompton M, Ferguson J, D Ramnath R, L Onions K, Ogier A, Gamez M
JCI Insight. 2023; 8(5).
PMID: 36749631
PMC: 10077489.
DOI: 10.1172/jci.insight.154164.
Phosphorylation of CaMK and CREB-Mediated Cardiac Aldosterone Synthesis Induced by Arginine Vasopressin in Rats with Myocardial Infarction.
Zhai Y, Li J, Peng L, Lu G, Gao X
Int J Mol Sci. 2022; 23(23).
PMID: 36499387
PMC: 9738971.
DOI: 10.3390/ijms232315061.
Aldosterone breakthrough as a clue to the physiological importance of paracrine regulation of aldosterone secretion.
Lopez A, Louiset E, Lefebvre H
Hypertens Res. 2022; 45(11):1832-1834.
PMID: 36028626
DOI: 10.1038/s41440-022-01009-9.
Aldosterone breakthrough from a pharmacological perspective.
Mogi M
Hypertens Res. 2022; 45(6):967-975.
PMID: 35422512
DOI: 10.1038/s41440-022-00913-4.
Drug Treatment of Heart Failure in Children: Gaps and Opportunities.
Weisert M, Su J, Menteer J, Shaddy R, Kantor P
Paediatr Drugs. 2022; 24(2):121-136.
PMID: 35084696
DOI: 10.1007/s40272-021-00485-9.
Autophagosome protects proximal tubular cells from aldosterone-induced senescence through improving oxidative stress.
Cao J, Ling L, Ni W, Guo H, Yang M
Ren Fail. 2021; 43(1):556-565.
PMID: 33757397
PMC: 7993373.
DOI: 10.1080/0886022X.2021.1902821.
Aldosterone antagonists for people with chronic kidney disease requiring dialysis.
Hasegawa T, Nishiwaki H, Ota E, Levack W, Noma H
Cochrane Database Syst Rev. 2021; 2:CD013109.
PMID: 33586138
PMC: 8094170.
DOI: 10.1002/14651858.CD013109.pub2.
Aldosterone antagonists in addition to renin angiotensin system antagonists for preventing the progression of chronic kidney disease.
Chung E, Ruospo M, Natale P, Bolignano D, Navaneethan S, Palmer S
Cochrane Database Syst Rev. 2020; 10:CD007004.
PMID: 33107592
PMC: 8094274.
DOI: 10.1002/14651858.CD007004.pub4.
The serum angiotensin-converting enzyme 2 and angiotensin-(1-7) concentrations after optimal therapy for acute decompensated heart failure with reduced ejection fraction.
Hisatake S, Kiuchi S, Kabuki T, Oka T, Dobashi S, Fujii T
Biosci Rep. 2020; 40(6).
PMID: 32458985
PMC: 7295637.
DOI: 10.1042/BSR20192701.
Effects of single and dual RAAS blockade therapy on progressive kidney disease transition to CKD in rats.
Aggarwal D, Singh G
Naunyn Schmiedebergs Arch Pharmacol. 2019; 393(4):615-627.
PMID: 31773183
DOI: 10.1007/s00210-019-01759-3.
The renin-angiotensin-aldosterone system and its suppression.
Ames M, Atkins C, Pitt B
J Vet Intern Med. 2019; 33(2):363-382.
PMID: 30806496
PMC: 6430926.
DOI: 10.1111/jvim.15454.
Mineralocorticoid Antagonism and Diabetic Kidney Disease.
Lytvyn Y, Godoy L, Scholtes R, van Raalte D, Cherney D
Curr Diab Rep. 2019; 19(1):4.
PMID: 30673886
DOI: 10.1007/s11892-019-1123-8.
Managing resistant hypertension: focus on mineralocorticoid-receptor antagonists.
Yugar-Toledo J, Modolo R, Faria A, Moreno H
Vasc Health Risk Manag. 2017; 13:403-411.
PMID: 29081661
PMC: 5652936.
DOI: 10.2147/VHRM.S138599.